Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Effects of cellular origin on differentiation of human induced pluripotent stem cell–derived endothelial cells
Shijun Hu, … , Michael P. Snyder, Joseph C. Wu
Shijun Hu, … , Michael P. Snyder, Joseph C. Wu
Published June 2, 2016
Citation Information: JCI Insight. 2016;1(8):e85558. https://doi.org/10.1172/jci.insight.85558.
View: Text | PDF
Research Article Stem cells Transplantation

Effects of cellular origin on differentiation of human induced pluripotent stem cell–derived endothelial cells

  • Text
  • PDF
Abstract

Human induced pluripotent stem cells (iPSCs) can be derived from various types of somatic cells by transient overexpression of 4 Yamanaka factors (OCT4, SOX2, C-MYC, and KLF4). Patient-specific iPSC derivatives (e.g., neuronal, cardiac, hepatic, muscular, and endothelial cells [ECs]) hold great promise in drug discovery and regenerative medicine. In this study, we aimed to evaluate whether the cellular origin can affect the differentiation, in vivo behavior, and single-cell gene expression signatures of human iPSC–derived ECs. We derived human iPSCs from 3 types of somatic cells of the same individuals: fibroblasts (FB-iPSCs), ECs (EC-iPSCs), and cardiac progenitor cells (CPC-iPSCs). We then differentiated them into ECs by sequential administration of Activin, BMP4, bFGF, and VEGF. EC-iPSCs at early passage (10 < P < 20) showed higher EC differentiation propensity and gene expression of EC-specific markers (PECAM1 and NOS3) than FB-iPSCs and CPC-iPSCs. In vivo transplanted EC-iPSC–ECs were recovered with a higher percentage of CD31+ population and expressed higher EC-specific gene expression markers (PECAM1, KDR, and ICAM) as revealed by microfluidic single-cell quantitative PCR (qPCR). In vitro EC-iPSC–ECs maintained a higher CD31+ population than FB-iPSC–ECs and CPC-iPSC–ECs with long-term culturing and passaging. These results indicate that cellular origin may influence lineage differentiation propensity of human iPSCs; hence, the somatic memory carried by early passage iPSCs should be carefully considered before clinical translation.

Authors

Shijun Hu, Ming-Tao Zhao, Fereshteh Jahanbani, Ning-Yi Shao, Won Hee Lee, Haodong Chen, Michael P. Snyder, Joseph C. Wu

×

Figure 4

In vitro maintenance of endothelial identity in iPSC-ECs.

Options: View larger image (or click on image) Download as PowerPoint
In vitro maintenance of endothelial identity in iPSC-ECs.
(A) EC-iPSC–EC...
(A) EC-iPSC–ECs generated from early passage iPSCs maintained a higher percentage of CD31+ cell population during long-time culture (20 days) than FB-iPSC–ECs and CPC-iPSC–ECs. *P < 0.05, 1-way ANOVA. (B–D) Similarly, EC-iPSC–ECs maintained higher EC marker (PECAM1) gene expression but lower expression in mesenchymal markers (ACTA2 and VIM) when compared with other iPSC-ECs during long-term culture. *P < 0.05, 1-way ANOVA. (E) TGF-β inhibitor SB431542 boosted CD31 expression in both EC-iPSC–ECs and FB-iPSC–ECs, though EC-iPSC–ECs maintained a higher percentage of CD31+ population than FB-iPSC–ECs. (F–H) EC-iPSC–ECs (day 20) showed higher expression of EC-specific marker PECAM1 (F, left) but lower expression of mesenchymal markers ACTA2 (G, left) and VIM (H, left) compared with FB-iPSC–ECs. In the presence of SB431542, EC-iPSC–ECs maintained higher expression of PECAM1 (F, right) and lower expression of ACTA2 (G, right) and VIM (H, right) than FB-iPSC–ECs. SB, SB431542. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired t-test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts